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INTRODUCTION 
 
Thyroiditis is one of the commonest thyroid diseases, being  particularly 
very common in south India (when compared to North India). 
 
However, in view of the diagnostic limitations in thyroid swelling, the 
this condition is often missed and thyroidectomy is performed on which is not 
only unnecessary, but also harmful to the patients, which is not only 
unnecessary, but also harmful to the patients, as it will lead to early and 
inevitable hypothyroidism. The patients are also at risk of early and late 
complications of thyroidectomy e.g. recurrent laryngeal nerve injury, 
hypoparathyroidism, neck scar, etc. 
 
Hence, the study is undertaken to elicit some of the diagnostic feature of 
the disease and thus to avoid surgery in these patients wherever possible. 
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AIM OF THE STUDY 
 
¾ To study incidence and epidemiological aspects (age, sex) of thyroiditis 
in a goitrous patients. 
¾ To find out the clinical features and presentation of thyroiditis in a 
goitrous patients. 
¾ To find out the status of investigations (hematologic, biochemistry, 
immunology, histopathology and imaging studies) 
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STUDY METHOD 
 
SETTING : Patients were selected from Medical Endocrinology Department 
and Surgical Endocrinology Department. 
STUDY DESIGN: prospective observational study. 
PERIOD: 2007 – 2009. 
ETHICAL CLEARANCE The study was approved by the hospital ethical 
committee. 
INFORMED CONSENT: Those who were willing to participate in the near1y 
after an informed consent were included in the study. 
INCLUSION CRITERIA: 
1. Clinical findings suggestive of  thyroiditis, supported by investigations. 
2. Final diagnosis affirmed by head of the department of Medical 
Endocrinology. 
3. Only newly diagnosed patients were included in the study. 
 
DIAGNOSTIC CRITERIA: 
Since a histological evidence of Hashimoto’s thyroiditis cannot be 
obstrainted practically routinely, the minimum requirement to diagnose a case 
as Hashimoto’s thyroiditis was taken as ‘positive AMA’ (most of the books 
quote that AMA antibodies are present in 100% of the cases) 
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CASE SELECTION CRITERIA: 
When history and clinical examination are suggestive of thyroiditis and 
it is supported by one or more of the three investigations (Thyroid function 
tests, Antimicrosomal antibody titer, FNAC). 
 
NUMBER OF PATIENTS 
Though the study started with- more than 300 patients, not all patients 
turned out for follow-up for complete investigations. 
 
¾ Only those patients who underwent all investigations were included in 
the study. For ease of calculation, 234 number of patients were selected.  
¾ The final diagnosis of all these 234 patients were confirmed by the head 
of the department of medical endocrinology & surgical endocrinology.  
 
EXAMINATION METHOD: 
¾ History from all patients were obtained by standard order of questioning 
as outlined in the Proforma given at end of this book. 
¾ All the patients were clinically examined by a single examiner to avoid 
observer bias. 
¾ FNAC smear was made by the same examiner and microscopic findings 
were noted by the same, with the help of a pathologist in the hospital. 23 
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gauge needle was used to aspirate cellular material and fixed 
immediately with 95% alcohol and stained H&E stain 
¾ Antimicrosomal antibody titer estimation was done by 
Radioimmunometric assay.  
¾ Thyoid hormonal assay was done by radioimmunoassay. 
¾ ESR was estimated by Westegren’s method. 
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REVIEW OF LITERATURE 
 
 
DEFINITION 
 
Thyroiditis is defined as inflammatory disorder of the thyroid aland. 
 
CLASSIFICATION OF THYROIDITIS 
 
 Acute (Suppurative) - Bacterial – staphylococcus, streptococus  
     Anaerobes, Fungal  
- Drug, Radiation induced thyroditis  
Subacute  - Granulomatous (De Quervains)     
- Lymphocytic (Silent, Painless) 
- Post partum thyroiditis  
Chronic   - Hashimoto’s (Autoimmune) 
   - Reidel’s  
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HASHIMOTO’S  THYROIDITIS 
 
It was first described in Japan by Hawkin Hashimoto in 1912 and is the 
most well known of  the immunological thyroid diseases. Hashimoto termed the 
disorder as ‘Struma lymphomatosa’ 
 
Over the last 50 years, the number of new cases diagnosed per year in 
U.S. has risen exponentially. In Hashimoto’s disease thyroid tissue damaged by 
immunological factors is replaced by lymphocytes, plasma cells and fibrosis. 
Antithyroid antibodies are present in the serum of patients with Hashimoto’s 
disease being first described in 1957 by Donsach and associates. 
 
Hashimoto’s thyroiditis has been linked to other autoimmune disease 
including vitiligo, Addison’s disease, Type I Diabetes Mellitus, Alopecia 
Sjogrens syndromes, Pernicious anemia, Lupus erythematoses, Rheumatoid 
arthritis, Myasthenia gravis and Idiopathic thrombocytopenic purpura. 
 
Other predisposing conditions to autoimmune thyroiditis include Down 
syndrome, familial Alzhiemer’ disease, and Turner’s syndrome. 
 
Hashimo to thyroiditis may rarely be associated with other endocrine 
disorders caused by the immune system. When Hashimoto’s disease occurs 
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with adrenal insufficiency and type I Diabetes mellitus, the condition is called 
Type 2 polyglandular autoimmune syndrome (PGA II). 
 
Less commonly, Hashimoto’s disease occurs with hypoparathyroidism, 
adrenal insufficiency and fungal infections of the mouth and nails iii it 
condition called Type I polyglandular autoimmune syndrome (PGJA I) 
 
ETIOLOGY AND PATHOGENESIS 
A current popular theory for the pathogenesis of HT is that it is a 
disorder of impaired immune surveillance, with dysfunction of normal 
‘suppressor’ T lymphocytes, allowing a clone of ‘helper’ T lymphocytes 
antigens, resulting in produce circulating to thyroid antibodies to thyroid 
destruction of thyroid cells. 
 
Patients with Hashimoto’s disease usually have detectable anti-thyroid 
antibodies at sometime in the course of their disease. The important cytotoxic 
effects of microsomal antibodies are increasingly recognized. 
 
Lymphocytes from patients with Hashimoto’s disease secrete 
lymphokines and undergo blast transformation when exposed to thyroid cells in 
vitro. The mechanism leading to anti thyroid antibodies formation and cell 
mediated immune reactivity has not been fully established. 
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Recently, however, it was suggested that HT may occur in absence of a 
systemic immune response. Baker et al. described a case of HT in which 
lymphocytes isolated directly from thyroid gland produced antibodies against 
Thyro globulin microsomal antigen, the thyroid cell membrane, and TSH, 
without there being serologic presence of thyroid autoantibodies. The authors 
suggested that intrathyroidal lymphocytes may be the source of thyroid directed 
antibodies. Thus, there may be more than one mechanism for the cellmediated 
immune response in HT.There appears to be a genetic predisposition for HT, as 
shown by its certain major histocompatibility complex antigens, such as HLA – 
B8 and HLA – DR5. 
Only hypothesis is that a local virus may be responsible. Viruses cause 
production of interferons, and gamma-interferon is a known inducer of DR 
antigen expression. Thus, in patients with genetic predisposition, a viral 
infection may indirectly cause induction of thyrocyte lILA-DR expression, 
resulting in a cascade of antigen production, antibody formation rni1 coil 
destruction. 
 
Another infectious agent, namely the gram-negative coccobacillus 
Yersinia enterocolitica is associated with positive thyroid autoantibodies and, 
conversely, antibodies to the Yersinia organism have been reported in between 
50% and 90% of patients with autoimmune thyroid disease. 
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In addition to infectious agents, certain environmental agents, including 
iodides, have been implicated in the pathogenesis of HT. studies in genetically 
susceptible animals have shown that potassium iodide supplements lead to a 
significant increase in antibody titers in blood as well as lymphocytic 
proliferation of the thyroid. The apparent sensitivity to iodides agrees with the 
 
clinical observation of an increasing prevalence of HT in industrialized, iodine 
– sufficient countries. 
 
PATHOLOGY 
 The enlarged thyroid is pale, firm and pale yellow with a fine nodular 
surface. Adjacent lymh nodes may be enlarge.d histologically, there is diffuse 
infiltration of the gland by lymphocytes and plasma cells, with formation of 
lymphoid dollicles and germinal centers. The thyroid follicles are disrupted, and 
the follicular basement membrane is damaged. Some epithelial cells are 
enlarged and show a characteristic oxyphilic change in the cytoplasm 
(Askenazy cells).The disease is usually focal but gradually extends to involve 
the whole gland. 
 As the lymphocytic infiltration progresses, the thyroid tissue degenerates 
and may be replaced by fibrous tissue. 
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CLINICAL FEATURES 
Middle aged women with grade I or II uniform enlargement of thyroid or 
obvious hypothyroidism are most likely to have Hashimoto’s thyroiditis. 
The most common presenting symptom is tightness in the throat, 
associated with a painless, nontender enlargement of the thyroid gland. 
Gland is firm and mildly enlarged (usually grade I or II). 
Enlargement is usually symmetrical, often granular on palpation. 
The thyroid may be 2 to 3 times enlarged than normal size and as the 
lobules become more prominent, it may be finely nodular on palpation. In some 
the gland is frankly nodular rather than diffusely enlarged. 
Pyramidal lobe may be enlarged. 
Tenderness is uncommon. 
Two different reports have been published- in one report, 100% of the 
patients had pain and tenderness over the gland; in another report, only 10% of 
the patients had tenderness over the gland. These observations stress the varied 
clinical presentations of HT. 
Most patients are euthyroid when the diagnosis is made. 
Approximately 20% of patients with Hashimoto’s thyroiditis present 
with signs and symptoms of hypothyroidism; 5% of patients with 
hyperthyroidism. (Hashitoxicosis). 
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In the atrophic form of the disease, the thyroid is normal and the medical 
attention for symptoms of hypothyroidism 
The prevalence of overt hypothyroidism increases with age. 
Large goiters may be associated with pressure symptoms. 
Compression of the trachea or a recurrent laryngeal nerve is rare. 
Rapid enlargement of the gland should raise the suspicion of thyroid 
lymphoma or carcinoma. 
Thyroid neoplasm is suspected clinically owing to asymmetry of the 
cervical lymphadenopathy, pressure symptoms, hoarseness, or enlargement of 
goiter despite adequate thyroid replacement. There is a relationship between 
thyroiditis and lymphoma. The tumour is rare but the risk of thyroid lymphoma 
is greatly increased in patients with Hashimoto’s disease, in Comparison with 
the general population. 
EPIDEMIOLOGY 
It is the most common cause of goitrous hypothyroidism in adults and 
sporadic hypothyroidism in children. 
 
World wide, the most common cause of hypothyroidism is iodine 
deficiency; however, Hashimoto’s thyroiditis remains the most common cause 
of spontaneous hypothyroidism in areas of adequate iodine intake. 
The incidence is 1-2 new cases per 1000 women per year.  
13 
 
Prevalance is 20cases per 1000 population. 
The disease is 10 to 15 times more common in women than men. 
The highest is in the age group of 20 to 40 years, peak incidence in men 
occurring 10 to 15 years later. 
The annual risk of developing clinical hypothyroidism is  about 4% 
when subclinical hypothyroidism is associated with positive TPO antibodies. 
It-is rare in children; very rare in children below 5 years. 
In adolescents, 40% of goiters are due autoimmune thyroiditis. 
It may be familial. 
Upto 50% of first degree relatives of patients with Hashimoto’s 
thyroiditis have thyroid antibodies inherited as a dominant trait. 
 It is more common in areas of iodine excess. 
It is common in certain populations such as the Japanese, probably as a 
consequence of genetic factors and chronic exposure to a high iodine containing 
diet. 
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DIAGNOSIS 
LABATORATY INVESTIGATIONS FOR THYROID DISORDERS 
HISTORY 
Over the last several decades there has been an explosion in the number 
laboratory investigations available to the physicians for assessing status of a 
patient. Initially the physician was limited to such crude measurements as 
serum cholesterol level and basal metabolic rate in an attempt to establish either 
hypo or hyper thyroidism. These tests were nonspecific and offered little more 
than what was obtained through clinical evaluation of the patient. The rapid 
growth in thyroid function testing began in the mid l950s when the protein 
bound iodide (PBI) determination became widely available. It was the first 
labarotary test that could quantitate the thyroid status of a patient. The 
physician’s ability to test the thyroid dysfunction improved with the 
introduction of competitive protein binding assay (1972) that more accurately 
measured of serum T4 levels. Estimates of free T4 levels as well as direct 
measures of biologically active free fraction of T4 recently have become 
available and play an integral role in modern thyroid function testing strategies. 
The major breakthrough, however in the arena of thyroid testing has been the 
development and evolution of the radio-immunoassay of thyrotropin(TSH), 
which serves as a readout of the endogenous free T4 levels in humans. 
Technological advancements in TSH assays have improved the ability to detect 
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the small changes in free T4 levels, allowing the physician to diagnose thyroid 
dysfunction earlier and to intervene before clinical disease is evident. Despite 
these laboratory methods, the doctor-patient relationship, a thorough history 
and a complete clinical examination remain critical in assessing the thyroid 
status of an individual. 
 
APPROACH 
 
Two fundamental questions need to be answered in the evaluation of a 
patient for possible underlying thyroid dysfunction, “what is the metabolic 
status of the patient?” and “what is the etiology of the disease?” 
 
An excellent gauge of thyroid status is either the free T4 concentration or 
the serum TSH levels. It will be shown that TSH measured by a sensitive assay 
offers the most reliable means of determining thyroid status in a given 
individual. In addition, because most thyroid disease directly involves the 
thyroid gland itself and is mediated by autoimmune process, the physician must 
assess the susceptibility of the thyroid gland to autoimmune mediated disease. 
Currently the measurement of antibody (AMA), also known as an anti-thyroid 
peroxidase antibody (TPO) titer, is the most sensitive marker for the detection 
of underlying autoimmune thyroid dysfunction. 
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The following paragraphs present a cost – effective approach to detect 
thyroid dysfunction and susceptibility of the thyroid disease in any given 
patient. The current role and the limitations of a single serum TSR level as a 
marker of thyroid status are addressed as well. Finally, common clinical 
situation in which discrepancies in the thyroid function occur and when more 
extensive thyroid testing strategies are indicated are discussed. 
 
Hashimoto’s thyroiditis is nearly always associated with positive 
antithyroid antibodies and positive AMA can be detected in sera of  
approximately 90% or more of the eases. Antithyroglobulin antibodies (ATA) 
are less frequently positive, being present in between 20% and 50% of cases. 
From a clinical stand-point, obtaining the AMA test is sufficient in order to 
confirm the diagnosis of HT. Although the AMA test is less specific than the 
ATA test, it is significantly more sensitive. When antibody titers were 
measured in cytologically proven HT, significant AMA titers were present in 61 
of 65 patients studies, whereas positive ATA titer were present in only 15 of 65 
patients. 
 
Clinically, the only tests necessary in patients in whom HT is suspected 
are the total serum T4, TSH level, and AMA test. 
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SERUM TSH ASSAYS 
The most significant advance in the area of thyroid function testing has 
been the improvement in the accuracy of measuring low serum concentration 
(normal range: 0.40- 4.5 mU/I). When first developed in 1965 and then made 
available in mid-1970s, TSH radioimmunoassay could reliably detect TSH 
values at a level of 1 mU/I, limiting their utility to those situations in which 
serum TSH levels would be elevated, i.e. hypothyroidism. When the 
development of monoclonal antibodies to TSH and resultant immunometric 
assays improved by an order of magnitude to 0.1 mU/i. Termed ‘sensitive’ TSH 
assays, they allowed the measurement of TSH to be used for the first time in the 
diagnosis of hyperthyroidism. 
The incorporation of chemoluminescent tags rather than radioisotopes in 
immunometric TSH assays had produced another order of magnitude of 
sensitivity, by which newer assays can routinely measure TSH concentrations at 
the 0.01 mU/l level. This has further improved the physician’s ability to reliably 
detect even milder form of thyroid hormone excess. Thus, assays capable of 
measuring TSH to the 0.1 mU/l level should be employed. Ideally, laboratories 
should offer assays that detect serum TSH at the 0.01 mU/l limit. These modern 
TSH methods should now be referred as second- generation (0.1mU/1 
sensitivity limit) or third – generation (0.01 mU/1 sensitivity limit TSH assays.) 
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(0.1 mUll sensitivity limit) or third-generation (0.01 mUll sensitivity limit) TSH 
assays. 
 
ANTIMICROSOMAL ANTIBODY TITERS 
The immune state of the thyroid gland should be evaluated to determine 
the etiology of thyroid disease, because the majority of thyroid disease with 
altered thyroid function encountered in a clinical practice is autoimmune in 
origin (Graves’ disease or Hashimoto’s thyroiditis). Currently the most widely 
available and accurate test is the measurement of the AMA or Anti TPO titer. In 
the past, hemagglutination methods were employed for the measurements of 
AMA titers, but they were plagued by both insensitivity and nonspecificity. 
Recently, immunoassay techniques have been developed to accurately measure 
serum AMA titers (normal range : <0.5 all) whereby values are positive in 
greater than 90% of patients with underlying autoimmune thyroid disease. 
Further it has been demonstrated that upto 15% of the general population have 
measurable AMA titers, with positive titers being more common in women than 
in men as well as in the older population. Upto 5% per year of patients with a 
positive AMA titer and normal TSH value develop some form of thyroid 
dysfunction. Thus, AMA titers have both diagnostic and prognostic utility in 
the evaluation of the patient with suspected thyroid disease. 
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Tests for thyroglobulin and microsomal antibodies should be performed 
because the presence and the titer of these antibodies correlate with the severity 
and extent of the autoimmune process. The titer regarded as positive varies in 
different laboratories and with the particular method and the reagents 
hypothyroidism associated with a goiter but negative thyroid antibodies suggest 
use of goitrogen, a dishormonogenetic goiter or an endemic goiter. Thyroid 
peroxidase antibodies (formerly called antimitochondrial antibodies) are present 
in more than 90% of cases and thyroglobulin antibodies are present in about 50 
% of the cases. 
 
TIIYROID FUNCTION TESTS 
 
Thyroid function tests should be performed to find out the hormone 
status. Patients are initially euthyroid but as the gland destruction progresses, 
hypothyroidism develops. Some patients in the early phase may develop 
hyperthyroidism. This is believed to be result from clones of lymphocytes that 
produce stimulatory anti TSH antibodies, creating a hyperthyroid status known 
as hashitoxicosis. 
 
Because the autoimmune process gradually reduces thyroid function, 
there is a phase of compensation during which normal thyroid hormone levels 
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are maintained by a rise in TSH. Though some patients have minor symptoms, 
this state is called subclinical hypothyroidism. Later free T4 levels fall and TSH 
levels rise further; symptoms become more readily apparent at this stage 
(usually TSH > 10 mUlL), which is referred to as clinical hypothyroidism 
(overt hypothyroidism). 
 
A normal TSH level excludes primary (but not secondary) 
hypothyroidism. If the TSH is elevated, a free T4 level is needed to confirm the 
presence of clinical hypothyroidism, but free T4 is inferior to TSH when a 
screening test, as it will not detect subclinical or mild hypothyroidism. 
Circulating T3 levels are normal in about 25% of patients, adaptive responses to 
hypothyroidism. T3 measurements are therefore not indicated. 
 
Once clinical or subclinical hypothyroidism is confirmed, the etiology 
usually easily established by demonstrating the presence of TPO antibodies, 
which are present in 90-95% of patients with autoimmune hypothyroidism. 
 
If there is any doubt about the cause of a goiter associated with 
hypothyroidism, FNAC can be used to confirm the presence of autoimmune 
thyroiditis. 
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ULTRA SONOGRAM 
Because of the superficial location of the thyroid gland, high resolution 
real time gray scale and color Doppler sonography can demonstrate normal 
thvroid anatomy and pathologic conditions with remarkable clarity. As a result, 
this technique has come to play an increasingly important role in the diagnostic 
evaluation of thyroid diseases. 
 
INSTRUMENTATION AND TECHNIQUE 
High resolution (7.5-15.0 MHz) currently provide both deep ultrasound 
penetration up to 5cm- and high deformation images, with a resolution of 0.7 to 
1.0 mm. No other imaging method can achieve this degree of spatial resolution.  
The patient is typically examined in the supine position with the neck 
extended. A small pad may be placed under the shoulders to provide better 
exposure of the neck, particularly in patients with a short, stocky habitus. The 
thyroid gland must be examined thoroughly in both transverse and longitudinal 
planes. Imaging of the lower poles can be enhanced by asking the patient to 
swallow, which momentarily raises the thyroid gland in the neck. Regional 
lymph node enlargement also should be looked for. 
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FINDINGS: 
In Hashimoto’ s thyroiditis, glandular enlargement is diffuse with a 
homogenous but coarsened parenchymal echotexture, generally more 
hypoechoic than a normal thyroid. 
 
Fibrotic septations may produce a pseudolobulated appearance of 
parenchyma. 
 
Multiple discrete, hypoechoic micronodules from 1 to 6 mm in diameter 
have been described as strongly suggestive of chronic thyroiditis. 
Histologically, they represent lobules of thyroid parenchyma which have been 
infiltrated by lymphocytes and plasma cells. These lobules are surrounded by 
echogenic fibrous strands. Micronodulation is a highly sensitive sign of chronic 
thyroiditis with a positive predictive value of 94.7%. But benign and ma1ignant 
thyroid nodules may coexist with chronic lymphocytic thyroiditis FNAC is 
often necessary to establish the final diagnosis. 
 
Hypervascularity occurs when hypothyroidism develops. 
 
Not infrequently, cervical lymphadenopathy is present especially 
affecting delphin node above thyroid isthmus. 
23 
 
The end-stage of chronic thyroiditis is atrophy where the gland is small 
with ill-defined margins, heterogenous texture due to progressive increase of 
fibrosis. Blood flow signals are absent. Occasionally discrete nodules occur and 
FNAC is needed to establish the diagnosis. 
  
Although the appearance of diffuse parenchymal inhomogeneity and 
micronodularity is quite typical of Hashimoto’s thyroiditis, other diffuse thyroid 
diseases most commonly adenomatous goiter, may have similar sonographic 
appearance. Some patients with adenomatous goiter have multiple discrete 
nodules separated by otherwise normal appearing thyroid parenchyma, other 
have enlargement with rounding of the poles of the gland, diffuse parenchyma, 
inhomogeneity and no recognizable normal tissue. 
Ultrasound is also extremely useful to find out or rule out other 
pathologies particularly thyroid carcinoma. Ultrasound guided FNAC should be 
done whenever suspicion of malignancy arises. 
 
FNAC 
FNAC examination of the thyroid gland is occasionally useful in 
confirming the diagnosis of Hashimoto’ s thyroiditis and in patients in whom 
malignancy is suspected. 
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The smears contain admixtures of lymphoid and epithelial cells in 
different proportions, depending on the stage of the disease. 
 
Colloid is scant or absent. 
In the late stage of the disease, fibrosis occurs and the aspirate may be 
poorly cellular. 
The epithelial component shows a spectrum of nuclear and cytoplasmic 
changes from follicular cells with minimal oxyphilic alterations to fully 
developed Hurthle cells. The cytoplasm is denser than in normal follicular 
epithelial cells. The nuclei are enlarged and reveal variable degress of nuclear 
atypia. The degree of pleomorphism may be extreme. The follicular epithelium 
presumably as a result of TSH stimulation may also nuclear atypia and 
abundant cytoplasm. Without clinical and laboratory data, the cytologic features 
may be misinterpreted as indicative of a neoplastic process. 
The lymphoid cells range from mature lymphocytes to small and large, 
cleaved and noncleaved, stimulated lymphocytes and immunoblasts. 
Multinucleated giant cells are seen in 30% of cases. 
When the lymphocyte component predominates, lymphoma should be 
considered. Lymphomas yield a monotonous, abnormal lymphoid population 
unlike the characteristic heterogenous lymphoid population of Hashimoto’s 
thyroiditis. 
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A lymphocytic infiltrate may co-exist with a neoplasm, particularly 
papillary carcinoma. Therefore special care should be taken in evaluating the 
follicular epithelial cells to exclude this possibility. 
The role of FNAC in excluding a malignancy, when doubt arises cannot 
be overemphasized. 
HISTOLOGY 
Histologically, two variants of Hashimoto’ s thyroiditis are recognized. - 
the classical and the fibrosing variety. 
The classic type is characterized by a diffuse lymphocytic and 
plasmacytic cellular infiltrate followed by formation of well-developed 
germinal centers. 
Thyroid follicles are small and can contain small amounts of colloid. 
The epithelial cells are enlarged and contain abundant dense eosinophilic 
cytoplasm as well as a hyperchromatic large nucleus. These so- called Hurthle 
cell changes or metaplasia can be extensive, forming clusters or rests, and are 
frequently found near or mixed with lymphoid aggregates. 
Fibrosis is apparent first in interlobular areas, but it can eventually 
replace areas of normal follicles. 
The fibrosing variant account for about 10% of all cases of hashimoto’s 
thyroiditis. Elderly patients present with large goitrous glands, severe 
hypothyroidism, and severe pressure symptoms. Grossly, the large well- 
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encapsulated glands have preservation of the lobular architecture. The 
histologic changes of typical Hashimoto’s thyroiditis are intermingled with 
diffuse broad bands of fibrous tissue containing lymphocytes and plasma cells 
that extensively replace the normal parenchyma. 
This variant can be distinguished from Riedel’s thyroiditis because it 
does not extend beyond the thyroid capsule, the latter involves the thyroid as 
well as other neck structures. 
A subacute variety of this condition causes transient pain and tenderness 
of the thyroid gland but in the majority of patients the thyroid enlargement 
changes over time from a rubbery consistency to stony hardness, associated 
with progressive hypothyroidism. 
Hashimoto’s thyroiditis can frequently be found coexisting with 
papillary carcinoma whether it represents an immunologic response to the 
tumor’s antigens is unclear. However, most of the reported cases that favour 
this association lack serologic evidence of Hashimoto’s thyroiditis. Therefore at 
present there is no evidence to support the malignant potential of this disease. 
Significant data do support the relationship between this process and the 
development of malignant lymphorna. 
ESR 
ESR is often raised in many patients with myxedema and 1-lashimoto’s 
thyroiditis. 
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ISOTOPE SCAN 
Thyroid isotope scanning usually reveals patchy uptake, and in general, 
provides little useful infonnation unless a dominant thyroid nodule is present. 
As with thyroid nodules in general, a dominant cold nodule in the setting of 
Hashimoto’s thyroiditis should be evaluated with FNAC to rule out primary 
lymphoma of thyroid as there is an association between Hashimoto’s thyroiditis 
and lymphoma of thyroid. Thus, lymphocytic subsets should be determined 
from the biopsy specimen if the more typical pathologic features of 
Hashimoto’s thyroiditis are not present. 
 
TREATMENT OF HASHIMOTO’S THYROIDITIS 
 
There is no specific treatment for hashimoto’s disease. Patients are 
usually followed medically, and replacement therapy is begun in patients with 
hypothyroidism or in patients with a goiter that is associated with pressure 
symptoms. Early initiation of thyroid hormone therapy is advised by many  
clinicians to prevent further thyroid enlargement and reduce the risk of 
myxedema. 
 
Reduction in goiter size with thyroxine is more commonly seen in 
younger patients and in whom TSH is elevated. 
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For patients with obstructive symptoms, corticosteroids may be helpful. 
Thyroxine therapy with long term follow-up monitoring of TSH levels is 
recommended. 
Many clinicians believe that the circulatory level of TSH is the single 
most sensitive test of thyroid function. 
If there is no residual thyroid function, the daily replacement dose of 
levothyroxine is usually 1.5 micrograms/kg body weight. In many patients, 
however, lower doses suffice until residual thyroid tissue is destroyed. 
In elderly individuals who may have underlying myocardial ischemia, 
the initial dose should start at 12.5 or 25µgm/day, and the dose can be increased 
gradually. 
The dose is adjusted on the basis of TSH levels, with the goal of 
treatment being a normal TSH, ideally in the lower half of their reference range. 
TSH responses are gradual and should be measured about two months after 
initiating treatment or after any subsequent change in levothyroxine dosage. 
The clinical effects of levothyroxine replacement are often slow to appear. 
Patients may not experience full relief from symptoms until 3 — 6 months after 
normal TSH levels are restored. Adjustment of levothyroxine is made in 12.5 
— 25 micrograms increments if the TSR is high; decrements of the same 
magnitude should be made if the TSH is suppressed. Patients with a suppressed 
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TSH of any cause, including T4 overtreatment, have an increased incidence of 
atrial fibrillation and reduced bone density. 
Once full replacement is achieved and TSH levels are stable, follow-up 
measurements of TSH is recommended at annual interval and may be extended 
to every 2 — 3 years, if a normal TSH is maintained over several years. It is 
important to ensure ongoing compliance, however, as patients do not feel any 
difference after missing a few doses of levothyroxine, sometimes leading to 
self-discontinuation. 
It is not uncommon to see discordant T4-TSH values in patients being 
treated for primary hypothyroidism. This discordance results from the lag in the 
pituitary response to changing serum thyroid hormone levels. The serum TSR 
may take several weeks or months to return to normal despite normalization of 
serum T4 values with levothyroxine therapy. The physician must be aware of 
this response when assessing the thyroid status in patients being treated for 
primary hypothyroidism. 
 
Patient education about the potential complications of mild, chronic 
hypothyroidism should help alleviate this worrisome practice. 
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INDICATIONS FOR SURGERY IN HASHIMOTO’S 
THYROIDITIS 
Surgical intervention is indicated for 
1. Obstructive symptoms, 
2. Cosmetically unacceptable goiter, 
3. When thyroid cancer (other than lymphoma) is found or suspected clinically. 
 
DEQUERVAIN THYROIDITIS (SUBACUTE) 
First reported in 1825, but de Quervain recorded its pathological 
description in 1904.4 
De Quervain (subacute granulomatous) thyroiditis is the most common 
cause of a painful thyroid gland. It is a transient inflammation of the thyroid, 
the clinical course of which is highly variable. Most patients have pain in the 
region of the thyroid, which is usually diffusely tender, and some have systemic 
symptoms. Hyperthyroidism often occurs initially, sometimes followed by 
transient hypothyroidism. Complete recovery in weeks to months is 
characteristic. 
 
Pathophysiology 
A viral infection or a postviral inflammatory response is presumed to 
cause de Quervain thyroiditis. Serial studies of viral antibody titers have 
31 
 
implicated many viruses (including coxsackievirus, Ebstein-Barr mumps, 
measles, adenovirus, echovirus, and influenza), but the changes could be 
attributed equally to nonspecific anamnestic responses. Viral inclusion bodies 
are not observed in thyroid tissue. 
A strong association exists with human leukocyte antigen (HLA)-B35 in 
most ethnic groups. A proposed mechanism is that the disease results from a 
viral infection that provides an antigen, either viral or resulting from virus-
induced host tissue damage, that uniquely binds to HLA-B35 molecules on 
macrophages. The antigen-HLA-B35 complex activates cytotoxic T 
lymphocytes that damage thyroid follicular cells because they have some 
structural similarity with the infection-related antigen. The transient presence of 
autoantibodies (eg, inhibitory immunoglobulins that bind to thyrotropin [TSH], 
antibodies that block thyroid stimulation, thyroid antimicrosomal antibodies, 
thyroglobulin [TGB] antibodies) has been noted in the acute phase of the 
disease, but their presence is attributed to a virally induced autoimmune 
response and is not implicated in the pathological process. In contrast with 
autoimmune thyroid disease, the immune response is not self-perpetuating; 
therefore, the process is limited. 
Destruction of follicular epithelium and loss of follicular integrity are the 
primary events in the pathophysiology of de Quervain thyroiditis. TGB, thyroid 
hormones, and other iodinatcd compounds are released into the blood, often in 
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quantities sufficient to elevate the serum thyroxine (T4) and triiodothyronine 
(T3) concentrations and suppress TSH secretion. This state lasts until the stores 
of TGB are exhausted or until healing occurs. New hormone synthesis 
temporarily ceases because of the low TSH. As inflammation subsides, the 
thyroid follicles regenerate and thyroid hormone synthesis and secretion 
resume. In some patients, several months are required for thyroid hormone 
synthesis to return to a normal rate; during that period, clinical hypothyroidism 
may be evident. 
Clinical 
History 
Some patients experience a flulike prodromal episode 1-3 weeks prior to 
the onset of clinical disease. The natural course of the disease can be divided 
into the following 4 phases that usually unfold over a period of 3-6 months. The 
acute phase, lasting 3-6 weeks, presents primarily with pain. Symptoms of 
hyperthyroidism also may be present. The transient asymptomatic and 
euthyroid phase lasts 1-3 weeks. The hypothyroid phase lasts from weeks to 
months, and it may become permanent in 5-15% of patients.  The recovery 
phase is characterized by normalization of thyroid structure and function.  
 
The diagnosis is made based on clinical findings. Prodromal flulike 
symptoms or known infectious disease, such as pharyngitis, measles, mumps, Q 
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fever, or typhoid fever, may occur. In young patients, de Quervain thyroiditis 
may develop following an episode of Henoch-Schonlein purpura. However, a 
history of prodromal symptoms often cannot be obtained. 
 
Local symptoms :- Pain over the thyroid area that is gradual or of sudden 
onset; that usually involves both lobes (in 30% of cases, it starts on one side and 
then migrates contralaterally within a few days); that radiates to the neck, ear, 
jaw, throat, or occiput; and is aggravated by swallowing and head movement; 
pain is the presenting symptom in over 90% of cases. Dysphagia,  Hoarseness 
(uncommon) 
 
Constitutional symptoms (often absent) :- Fever, Malaise, Anorexia, Fatigue, 
Muscle aches 
 
Symptoms of hyperthyroidism:- (palpitations, tremulousness, heat 
intolerance, sweating, nervousness) occurring in the initial phase of the disease, 
Hyperthyroidism that usually is mild and rarely is severe, Transient symptoms, 
usually lasting 3-6 weeks 
 
Symptoms of hypothyroidism:- occurring in the late phase of the disease in as 
many as half the cases, mostly mild or moderate, Transient hypothyroidism in 
90-95% of cases 
Hypothyroidism :- lasts weeks to months 
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Physical 
Thyroid tenderness is usually symmetrical, but, occasionally, it starts in 
one lobe and then involves the contralateral lobe. Often, the pain is so severe 
that the patient cannot tolerate palpation of the neck. Thyroid enlargement is 
usually symmetric and mild, occasionally with areas of localized firmness. 
Erytbema and hyperesthesia of the overlying skin may be present at the 
onset of severe cases. Cervical lymphadenopathy is uncommon. 
Hyperthyroidism.  
 
Causes 
A viral infection or a postviral inflammatory response in genetically 
predisposed individuals is presumed to cause de Quervain thyroiditis. Serial 
studies of viral antibody titers have implicated many viruses (including 
coxsackievirus, Ebstein-Barr, mumps, measles, adenovirus, echovirus, and 
influenza), but the changes could be attributed equally to nonspecific 
anamnestic responses. Recent studies failed to demonstrate significant chanves 
in serum antiviral antibody titers, or to detect viral DNA in the thyroid 
specimens. 
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INVESTIGATIONS 
Laboratory Studies 
Usually, the diagnosis is made on clinical grounds, and the only laboratory 
studies needed initially are those to determine whether hyperthyroidism is 
present, including TSH and free T4. If any doubt exists as to whether de 
Quervain thyroiditis is the correct diagnosis, 2 other tests may be helpful.  
Serum thyroglobulin is almost always markedly elevated. Erythrocyte 
sedimentation rate (ESR) is usually higher than 50mm/h in the initial phase. A 
normal or slightly elevated ESR makes the diagnosis of de Quervain thyroiditis 
relatively unlikely. ESR falls as the inflammatory process resolves, but 
following the ESR provides no useful information beyond what clinical 
observation yields. 
After the initial inflammatory phase subsides, TSH should be monitored 
at intervals of 4-6 weeks for a few months to determine whether 
hypothyroidism occurs. Antibodies to TGB, thyroid peroxidase, and TSH 
receptor are usually absent in de Quervain thyroiditis and need not be sought 
unless the clinical differential diagnosis includes immune thyroid disease 
(Graves disease, chronic lymphocytic [Hashimoto] thyroiditis). In rare cases 
with systemic multiorgan involvement, elevation of serum alkaline 
phosphatase, gamma-glutamyl transpeptidase, aminotransferascs, and 
pancreatic enzymes may occur. Glucose intolerance has been reported. 
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Imaging Studies 
• Ultrasonography of the thyroid gland 
Ultrasonography provides no additional information and N rarely 
indicated for diagnostic purposes. In the first 3 phases of the disease, the 
thyroid gland is enlarged, shows unclear contour, and is diffusely or focally 
hypoechogenic. In the recovery phase, the thyroid structure and dimensions 
return to normal.  Fibrosis is observed in some patients as hyperechogenicity 
and may occur as a form of healing. Extensive fibrosis is a predictor of 
hypothyroid state.  
Doppler ultrasonography shows a near absence of vascularization in the 
acute phase and slightly increased vascularization in the recovery phase. During 
the acute phase, the more affected areas in the thyroid gland show the greatest 
decrease in vascularization, with the echogenically healthy-appearing regions of 
the thyroid showing normal or slightly increased vascularization. 
Ultrasonographic abnormalities are not correlated with the intensity of the 
inflammatory syndrome and/or thyroid function status. Recurrence can be seen 
as a new thyroid enlargement and an extension of hypoechoic regions. Risk of 
recurrence is not correlated with the initial ultrasonographic aspect, and there 
are no significant differences between patients with and without recurrence 
concerning the initial thyroid volume or echogenicity.  
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• CT scanning of the neck 
CT scanning of the neck is not indicated for the diagnosis of thyroiditis. 
Consider that the administration of iodinated contrast material before measuring 
radioiodine uptake may result in a falsely decreased iodine uptake. If CT 
scanning is planned, it should be performed after any radioiodine uptake studies 
are completed. 
The normal thyroid gland has a high attenuation (80-100 HU) because the 
normal thyroid gland concentrates iodine almost 100 times more than does the 
serum. In subacute thyroiditis, a diffusely swollen thyroid gland is observed, 
with a low attenuation corresponding to 45 HU. There is also moderate 
enhancement of the thyroid gland on contrast-enhanced scanning, suggesting 
the diffuse inflammatory nature of the disease process. 
• Magnetic resonance imaging: MRI is not indicated for the diagnosis or 
evaluation of subacute granulomatous thyroiditis. If one is performed 
during the acute phase, the thyroid gland shows irregular margins and a 
higher than normal T1-weighted signal intensity and a much higher than 
normal T2-weighted signal intensity. 
Neither radioiodine uptake (RAIU) nor thyroid scanning is indicated 
unless pain is mild or absent, in which case Graves disease might be considered 
in the differential diagnosis. RAIU is very low in the initial phase of subacute 
thyroiditis (<1-2% at 24 h) but usually is elevated in Graves disease. 
38 
 
Technetium-99m-pertechnetate scintigraphy typically demonstrates markedly 
reduced uptake in the thyroid gland during the acute stage, but this finding is 
not present in all patients.  Technetium-99m-tetrafosmin uptake correlates with 
the stage of disease, particularly with inflammation, and shows increased 
uptake in the damaged area during the acute phase. However, this procedure is 
rarely used in the United States. Technetium-99m-sestamibi scanning may 
show diffuse increased uptake in the region of the thyroid gland, suggesting 
increased perfusion. The clearance rate of Technetium-99m-sestamibi during 
the early phase (ie, from 10 mm to 1 h) is decreased in the acute stage of 
subacute granulomatous thyroiditis 
 
• Fine-needle aspiration of the thyroid  
Fine-needle aspiration (FNA) is rarely needed; most of the time, the 
diagnosis of de Quervain thyroiditis can be made solely on clinical grounds. 
Some authors advocate that FNA should be performed in all patients with a 
tender thyroid to avoid misdiagnosis and inappropriate management. FNA is 
useful for diagnosis when atypical presentations of thyroid carcinoma and 
thyroid abscess are considered in the differential diagnoses. It usually shows the 
specific histological features of de Quervain thyroiditis (see Histologic 
Findings). FNA may provide unclear results in the acute stage when atypical 
follicular cells may appear in the aspirate, mimicking thyroid carcinoma. 
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Histologic Findings 
Macroscopic 
The thyroid gland is moderately enlarged and edematous in de Quervain 
thyruiditis. It may be unilaterally or bilaterally enlarged and has an intact 
capsule. Affected areas are firm find yellow-white and stand out from the more 
rubbery, normal, brown thyroid substance. 
Microscopic 
The changes are patchy and vary with the stage of the disease. The early 
phase is the active inflammatory phase and is characterized by areas of entirely 
disrupted follicles, which are replaced by neutrophils, forming microabscesses. 
In a later phase, the classic changes of granulomatous thyroiditis develop. This 
is characterized by aggregations of lymphocytes, large histiocytes, and plasma 
cells among damaged thyroid follicles. Multinucleated giant cells enclose pools 
or fragments of colloid, from which stems the designation giant cell thyroiditis. 
Colloid is also found within the giant cells, following a process called 
colloidophagy. In the final stages, the areas of injury are replaced by a chronic 
inflammatory infiltrate and fibrosis. Different histologic stages sometimes are 
found in the same gland, suggesting waves of destruction over a period of time. 
 
Under a scanning electron microscope, the cytomorphology of subacute 
granulomatous thyroiditis shows loss of a uniform honeycomb cellular 
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arrangement, variation in size and decreased or shortened microvilli in 
follicular cells, and the appearance of round or ovoid giant cells. The giant cells 
are closely associated with the granulomas, and are CD68+, thyroglobulin 
negative, and cytokeratin negative. The small lymphocytes in the granulomas 
are CD3+, CD8+, CD45RO+ cytotoxic T cells. In the nongranulomatous lesions, 
the follicles are infiltrated by CD8+ T lymphocytes, plasmacytoid monocytes, 
and histiocytes, resulting in disrupted basement membrane and rupture of the 
follicles. These findings suggest that cellular immune response may play an 
important role in the pathogenesis of subacute thyroiditis. 
 
Treatment 
Medical Management  
Management is directed towards 2 problems-pain and thyroid 
dysfunction. 
• Pain 
Some patients with mild pain require no treatment. Nonsteroidal anti- 
inflammatory drugs (NSAIDs), such as ibuprofen (800-1200 mg/d in divided 
doses) or naproxen (1-1.5g/d in divided doses), or aspirin (2-4 g/d in divided 
doses) are used. Treatment can be tapered as allowed by the patient’s pain. 
Analgesic therapy can usually be stopped after 2-6 weeks.  
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Steroids have no proven superiority to NSAIDs in de Quervain 
thyroiditis and should be avoided. If NSAIDs provide insufficient relief of pain 
within 3 days, then prednisone may be tried at 30-40 mg/d initially. The 
response to prednisone is usually prompt (within 2-3 d), and, if a prompt 
response does not occur, prednisone should be stopped. The dose of prednisone 
should be tapered slowly; symptoms often recur upon withdrawal. 
If pain does not respond within 3 days, the diagnosis should be 
reconsidered. 
• Management of thyroid dysfunction 
In the initial phase of de Quervain thyroiditis, symptomatic 
hypcrthyroidiim can be treated with beta-blockade (propranolol 10-20mg qid or 
atenolol 25-0 mg/d), although mild symptoms may not require treatment. Beta-
blockade, if needed, can usually be withdrawn in 2-6 weeks. Antithyroid drugs 
are of no value because the excess T4 and T3 results from release of preexisting 
thyroid hormone by follicular damage rather than from active synthesis.  
If hypothyroidism occurs during the late phase, it is usually mild and 
transient. If symptoms are present or TSH is elevated, the patient needs 
replacement therapy with levothyroxine. Depending on the level of TSH, the 
starting dose can be 25-100 mcg/d and is adjusted for normalization of TSH. 
Usually, the hypothyroid stage lasts 2-3 months, but some authors recommend 
treatment for as long as 6 months, followed by discontinuation and monitoring 
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of TSH. Rare cases with permanent hypothyroidism require lifelong 
replacement therapy. 
Surgical Management 
No surgical treatment is required in de Quervain thyroiditis. 
Diet 
Diet modification has no role in the management of de Quervain 
thyroiditis. 
Medication 
The goals of pharmacotherapy are to reduce disease-associated 
morbidity and prevent complications due to abnormal thyroid function. No 
treatment has been shown to impact the occurrence of permanent 
hypothyroidism. 
Salicylates 
Used for symptomatic treatment. Aid in the relief of mild to moderate 
pain by inhibiting inflammatory reactions and pain. 
Aspirin (Anacin, Ascriptin, Bayer Aspirin, Bayer Buffered) 
NonsteroidaI anti-inflammatory drugs 
Although most NSAIDs are used primarily for their anti-inflammatory 
effects, they are effective analgesics and are useful for the relief of mild to 
moderate pain. 
Naproxen(Aleve, Naprelan, Naprosyn, AnaProx) 
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For relie\of mild to moderate pain. Inhibits inflammatory reactions and 
pain by decreasing activity of\cyclooxygenase, which results in a decrease of 
prostaglandin synthesis. 
 
Glucocorticoids  
 Have anti-inflammatory properties and cuase profound and varied 
metabolic effects. They modify the body’s immune response to diverse stimuli.  
Beta-adrenergic blocking agents  
 Used for symptomatic relief of hyperthyroidism. Propranolol is used as 
an example, but any noncardioselective beta-blocker can be used. Use only in 
moderate to severe cases of hyperthyroidism, and many times it is not needed.  
Propranolol (Inderal, Betachron E-R)  
 
Thyroid hormones 
Required during the recovery phase if transient hypothyroidism occurs. 
Required indefinitely in the occasional patient who develops permanent 
hypothyroidism. 
Levothyroxine (Levothroid, Levoxyl, Synthroid) 
 
DOC. In active form, influences growth and maturation of tissues. 
Involved in normal growth, metabolism, and development. 
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Adult 
Transient hypothyroidism (symptom relief): 25-100 mcg/d PO 
Permanent hypothyroidism: 1.6 mcg/kg PO 
Pediatric 
Neonate to 6 months: 25-50 mcg/d PO 
6-12 months: 50-75 mcg/d PO 
1-5 years: 75-100 mcg/d PO 
6-12 years: 100-150 mcg/d PO 
>12 years: 150 mcg/d PO 
Follow-up 
Inpatient care is only recommended in the rare cases in which severe 
symptomatic hyperthyroidism is present. The authors recommend monitoring 
thyroid function every 2-4 months for 1 year or until thyroid function 
normalizes (whichever occurs later). Yearly monitoring of thyroid function 
should be performed thereafter for several years, since permanent 
hypothyroidism may occur several years following the initial diagnosis. 
 
Complications 
• Acute complications 
Severe hyperthyroidism may be observed during the inflammatory phase (see 
History). Multiple system organ failure may complicate the course of the 
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disease in exceptionally rare cases. Pancreatitis or splenomegaly has been 
associated with de Qucrvain thyroiditis in case reports only.  Vocal cord 
paralysis occurs occasionally in cases with severe thyroid gland inflammation. 
Cerebral venous thrombosis was reported in some cases. In one case, the patient 
was a heterozygous carrier for the G202 10A mutation of the prothrombin gene, 
which predisposed her to this complication. 
• Long-term complications 
Permanent hypothyroidism is the most frequent long-term complication of de 
Quervain thyroiditis. It is observed in less than 510% of the patients and 
requires thyroid replacement therapy. Disease recurrence has been documented 
in occasional cases (up to 20% of cases in some series). Recurrence is more 
frequent in the first year but has been reported even 30 years after the initial 
diagnosis. The risk of recurrence cannot be correlated with initial thyroid 
function, inflammatory syndrome, or ultrasonographic aspect (ie, thyroid 
volume. echogenicity). 
Prognosis 
Prognosis is excellent. More than 90% of the patients with de Quervain 
thyroiditis recover completely, with or without treatment. Even in the 5-10% of 
patients who develop hypothyroidism, treatment with thyroid hormone is 
effective. 
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RIEDEL’S THYROIDITIS 
Riedel thyroiditis, or Riedel’s thyroiditis (RT), is a rare, chronic 
inflammatory disease of the thyroid gland characterized by a dense fibrosis that 
replaces normal thyroid parenchyrna. The fibrotic process invades adjacent 
structures of the neck and extends beyond the thyroid capsule. This feature 
differentiates RI from other inflammatory or fibrotic disorders of the thyroid. 
Because of the encroachment beyond the thyroid capsule, other problems can 
be associated with RI, including hypoparathyroidism, hoarseness (due to 
recurrent laryngeal involvement), and strider (due to tracheal compression). 
Some experts feel that RT is not primarily a thyroid disease but rather that it is a 
manifestation of the systemic disorder rnultifocal fibrosclerosis. Approximately 
one third of RT cases are associated with clinical findings of multifocal 
fibrosclerosis at the time of diagnosis. 
In 1883, Professor Bernhard Riedel first recognized the disease. He 
published a description of 2 cases in 1896 and of a third case in 1897.1 Riedel 
used the term eisenharte strums to describe the stone-hard consistency of the 
thyroid gland and its fixation to adjacent structures. He noted the presence of 
chronic inflammation with fibrosis and the absence of malignancy on 
microscopic examination. Simple wedge resection of the thyroid isthmus was 
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used to alleviate tracheal obstruction and is still the preferred surgical therapy 
for RT. 
Pathophysiology 
The etiology of Rieders thyroiditis (RT) is unknown. One theory of 
pathogenesis postulates that RT results from an autoimmune process. A second 
theory holds RT to be a primary fibrotic disorder. 
 
The following evidence supports an autoimmune pathogenesis for RT: 
The presence of antithyroid antibodies in a significant percentage of 
patients with RT (67% of 178 cases reviewed in one study). The pathological 
features of cellular infiltration, including lymphocytes, plasma cells, and 
histiocytes. The frequent presence of focal vasculitis on pathologic 
examination. The favorable response of a subset of patients with RI to treatment 
with systemic corticosteroids 
However, the presence of normal lymphocyte subpopulations and normal 
serum complement levels weighs against an autoimmune mechanism. 
Additionally, elevated levels of antithyroid antibodies may merely reflect the 
immune system’s exposure to sequestered antigens released by the destruction 
of thyroid parenchyma from a primary fibrotic disorder. 
The theory that RT is a primary fibrotic disorder is supported by its 
association with rnultifocal fibrosclerosis. This uncommon idiopathic syndrome 
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is characterized by fibrosis involving multiple organ systems. The extra cervical 
manifestations of multifocal fibro sclerosis can include retroperitoneal fibrosis, 
mediastinal fibrosis, orbital pseudotumor, pulmonary fibrosis, sclerosing 
cholsngitis, lacrimal gland fibrosis, and fibrous parotitis. RI may be but 1 
manifestation of this multifocal disease. 
The histopathologic changes of RT closely resemble those observed in 
multifocal fibrosclerosis. Additionally, one third of published RI cases have 
demonstrated at least one manifestation of extracervical fibrosclerosis. The 
ability of systemic corticosteroids and tamoxifen to inhibit fibrogenesis 
accounts for the favorable effect of such treatment in both conditions. 
 
CLINICAL  
History 
Riedel’s thyroiditis (RT) is characterized by the replacement of normal thyroid 
parenchyma with dense fibrotic tissue and by the extension of this fibrosis to 
adjacent structures of the neck. Patients typically present with a hard, fixed, 
painless goiter. The character of the thyroid gland is often described as stony or 
woody. The onset of the goiter may be sudden, but it is usually gradual. 
Involvement may be unilateral or bilobar. Thyroid function depends on the 
extent to which the normal thyroid  gland has been replaced by fibrotic tissue. 
Most patients are euthyroid. Hypothyroidism is noted in approximately 30% of 
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cases. Rarely, hyperthyroidism can occur, but this is probably secondary to a 
coexisting condition. 
Local compressive symptoms, such as neck tightness or pressure, dyspnea, 
dysphagia, hoarseness, choking, and cough, are frequent. Such symptoms are 
the result of the increasing thyroid mass or are due to the extension of the 
fibrotic process to adjacent neck structures (eg. strap muscles, trachea, 
esophagus, recurrent laryngeal nerve). Hypoparathyroidism is rare and 
presumably reflects fibrotic involvement of the parathyroid glands. Recurrent 
laryngeal nerve paralysis is also uncommon, but it can be observed in extensive 
disease. Occasionally, spontaneous remission has been reported. Patients can 
also relapse. 
 
Physical 
Clinical features of Riedel’s thyroiditis (RT) closely resemble those of 
anaplastic carcinoma of the thyroid. Patients note a nonpainful, rapidly growing 
thyroid mass. One distinguishing feature of RT is the absence of associated 
cervical adenopathy. However, accurate diagnosis requires open biopsy. RT and 
anaplastic carcinoma of the thyroid can be distinguished by 
mmunohistochemistry. 
Approximately one third of patients with RT have an associated 
extracervical manifestation of multifocal fibroscierosis (eg. retroperitoneal 
50 
 
fibrosis, mediastinal fibrosis, orbital pseudotumor, pulmonary fibrosis, 
scierosing cholangitis, lacrimal gland fibrosis, fibrosing parotitis). 
 
Causes 
The etiology of Riedel’s thyroiditis is unknown. 
 
INVESTIGATIONS 
Laboratory Studies 
The laboratory findings of Riedel’s thyroiditis (RT) are nonspecific. The 
erythrocyte sedimentation rate (ESR) is generally elevated. Most patients 
remain euthyroid. Approximately 30% of patients become hypothyroid. Rarely, 
patients are hyperthyroid. In one review, antithyroid antibody levels (TG-Ab 
and TPO-Ab) were found to be elevated in 67% of 170 cases.2 However, it is 
not certain whether such autoantibodies are pathogenic or whether their 
presence merely reflects exposure of the immune system to sequestered 
antigens released by the fibrotic destruction of normal thyroid parenchyma. 
 
Imaging Studies 
In cases of Riedel’s thyroiditis (RT), imaging studies may suggest the 
diagnosis, but findings can be nonspecific. Enlargement of the affected thyroid 
gland and compression or invasion of adjacent structures, such as the strap 
muscles, trachea, esophagus, or carotids, may be observed on computed 
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tomography (CT) or magnetic resonance imaging (MRI) scans. However, these 
studies cannot reliably distinguish between RT and invasive thyroid 
malignancy. 
CT scanning shows affected areas of the thyroid to be hypodense. The 
area is usually isodense with the neck muscles. The use of iodinated contrast 
has occasionally been reported as causing increased enhancement, but usually it 
is decreased, especially if extensive fibrosis is present. On MRI scans, the 
affected thyroid gland is typically hypointense on T1- and T2-weighted images. 
Decreased enhancement has usually been reported with gadolinium contrast 
use, but occasionally. 
 
Medical Management 
The rarity of Riedel’s thyroiditis (RT) makes controlled studies of RT 
therapy impractical. Recommendations for medical treatment have been largely 
based on empirical experience. 
Currently, corticosteroid therapy is the medical treatment of choice for 
patients with RT. Most studies note a reduction in goiter size and the relief of 
local compressive symptoms, although some patients show no benefit. 
Some investigators believe that a favorable response is more likely early 
in the course of the disease. Improvement is less likely to occur in patients with 
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advanced RT when the affected portions of the thyroid gland have been 
completely replaced by fibrotic tissue. 
Corticosteroids are believed to act by reducing inflammation and by 
inhibiting the actions of fibrinogenic cytokines. No consensus has been reached 
on the corticosteroid dosing regimen. However, all studies advocate an initially 
high dose to alleviate compressive symptoms, followed by gradual tapering 
over months to a lower maintenance dose. 
The effectiveness of therapy can be judged by symptomatic 
improvement and by following the reduction of the ESR and the thyroid 
autoantibody levels. Many patients can be weaned from therapy, but others 
require more prolonged treatment. 
Tamoxifen has been used in RT patients as a first-line therapy, but it has 
also been employed after the failure of corticosteroid treatment. The usual dose 
that has been found to be effective is 20 mg taken orally twice a day. Patients 
who respond can be tapered to 20 mg once each day or to 10 mg twice a clay. 
Because of the relatively infrequent occurrence of RT, comparison studies with 
tamoxilen and steroid therapy have not been undertaken. Few and colleagues 
initially advocated tamoxifen in a study of 4 patients with progressive RT who 
were not responsive to corticosteroids or surgical decompression Each patient 
had a decrease of 50% or more in the size of the thyroid mass, with one patient 
having total resolution. Since then, additional reports have described successful 
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treatment of EU with tamoxifen. An oral dose of 20 my twice a day provided 
each patient with symptomatic improvement, as well as a reduction in the size 
of the involved tissue as measured on CT scan. 
Estrogen receptors have not been demonstrated in RT tissue. Therefore, 
the mechanism of action was not proposed to be tamoxifen’s antiestrogen 
activity but rather its induction of transforming growth factor beta, a potent 
inhibitor of fibroblast proliferation. Use levothyroxine therapy to correct 
hypothyroidism associated with RT. Many authorities advocate not only thyroid 
replacement but also suppression of thyroid-stimulating hormone (TSH) in all 
patients with RT, regardless of thyroid function. However, the degree to which 
TSI-I stimulates the fibroinflammatory processes of RT, if at all, is unknown. 
As such, recommendations for TSH suppression must be regarded as empirical. 
 
Surgical Management 
Surgery for patients with Riedel’s thyroiditis (RT) serves the dual 
purpose of establishing the diagnosis and relieving tracheal compression. A 
wedge resection of the thyroid isthmus remains the preferred method for 
accomplishing these ends. Surgery is indicated when tissue is needed for 
diagnosis, medical treatment shows no benefit, or compressive symptoms are 
very severe. 
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Open surgical biopsy is essential to the definitive establishment of the 
diagnosis of RT and to the exclusion of carcinoma. 
A wedge resection of the isthmus relieves tracheal compression. Grossly, 
the affected tissue is stony and hard and is white or pale gray. It has a similar 
feel to cartilage when incised.  
More extensive thyroid surgery is generally discouraged because extra 
thyroid fibrosclerosis alters the anatomy and obliterates surgical planes. The 
trachea, esophagus, carotids, recurrent laryngeal nerves, or parathyroid glands 
may be encased by fibrotic tissue and are at increased risk for iatrogenic 
surgical damage. 
 
Medication  
The goals of pharmacotherapy are to reduce morbidity and prevent 
complications. 
Corticosteroids 
Have anti-inflammatory properties and cause profound and varied 
metabolic effects. Corticosteroids modify the body’s immune response to 
diverse stimuli. 
Prednisone (Deltasone, Meticorten, Orasone, Sterapred) 
Immunosuppressant for the treatment of autoimmune disorders. 
Prednisone may decrease inflammation by reversing increased capillary 
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permeability and suppressing PMN activity. The drug stabilizes lysosomal 
membranes and suppresses lymphocytes and antibody production. 
Antineoplastic agents  
 For progressive Riedel’s thyroiditis that is not responsive to 
corticosteroids or surgical decompression, on for with contraindications to 
corticosteroid therapy. Antineoplastic agents provide symptomatic 
improvement, well as size reduction of the involved tissue as measured on CT 
scans.  
Thyroid hormones 
Used to correct hypothyroidism associated with RiedeEs thyroiclitis. 
Levothyroxine (Levothroid, Levoxyl, Synthroid, Unithroid) 
Rapidly inhibits the release of thyroid hormones via a direct effect on the 
thyroid gland; it also inhibits the synthesis of thyroid hormones. Iodide also 
appears to attenuate cAMP-mediated effects of TSH. In active form, 
levothyroxine influences the growth and maturation of tissues. It is involved in 
normal growth, metabolism, and development. 
Follow up 
The patient with Riedels thyroiditis should be followed for progression 
of the disease and for the development of multifocal fibrosclerosis. Repeat 
imaging of the neck by CT scanning or MRI should be performed at intervals 
defined by the rate of progression.  
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The patient’s TSH level should be routinely checked and maintained in 
the reference range, with levothyroxine administered as necessary. 
Complications 
• Airway obstruction 
• Dysphonia 
• Hoarseness 
• Hypothyroidism 
• Hypoparathyroidism 
• Dysphagia 
Prognosis 
Riedel’s thyroiditis (RT) is generally a self-limited disease with a 
favorable prognosis. Death due to airway compromise is very rare. One third of 
patients with RT ultimately develop at least 1 extracervical manifestation of 
multifocal fibrosclerosis (such as retroperitoneal fibrosis. mediastinal fibrosis, 
or sclerosing cholangitis. In such patients, the prognosis essentially becomes 
that of extra cervical fibrosclerosis. Therefore, when RT is diagnosed, it is 
essential to perform abdominal and chest imaging studies to exclude 
concomitant, extra cervical entities from multifocal fibro sclerosis. 
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ACUTE (SUPPURATIVE) THYROIDITIS 
 
 
The thyroid gland is inherently resistant to infection as a consequence of 
its extensive blood and lymphatic supply, high iodide content, and fibrous 
capsule, but infectious agents can seed it (1) via the hematogenous or lymphatic 
route; (2) via direct spread from persistent pyriform sinus fistulae or 
thyroglossal duct cysts;  (3) as a result of penetrating trauma to the thyroid 
gland: or (4) as a result of immunosuppression. Streptococcus and anaerobes 
account for about 70% of cases, but escherichia coli, Pseudomonas aeruginosa, 
Haemophilus influenzae. Eikenella Corrodens, corynebacterium, and 
Coccidimyosis species also have been cultured. Acute suppurative thyroiditis is 
more common in children and is often preceded by an upper respiratory tract 
infection or otitis media. It is characterized by severe neck pain radiating to the 
jaws or ear lever, chills, odynophagia and dysphonia. Rarely, complications 
such us systemic sepsis, tracheal or esophageal rupture, jugular vein 
thrombosis, laryngeal chondritis or perichondritis and sympathetic trunk 
paralysis may result.  
The diagnosis is established by leukocytosis on blood tests and FNA 
biopsy for Gram’s stain, culture, anti cytology. CT scans may help to delineate 
the extent of infection. A persistent pyriform sinus fistula should always be 
58 
 
suspected in children with recurrent acute thyroiditis. A barium swallow 
demonstrates the anomalous tract with 80% sensitivity.  
 
Treatment consists of parenteral antibiotics and drainage of abscesses. 
Patients with pyriform sinus fistulae require complete resection of the sinus 
tract, including the area of the thyroid where the tract terminates, in order to 
prevent recurrence.  
 
DRUG INDUCED THYROIDITIS 
Many medication can alter thyroid function or the results of thyroid 
function tests. However, only few, are known to provoke autoimmune or 
destructive inflammatory thyroiditis. 
AMIODARONE  
Amodarone induced hypothyroidism occurs in patients with pre existing 
thyroid autoimmunity, while receiving amiodarone, Treatment is given with 
levothyroxine sodium and amiodarone may be continued. 
Amiodarone induced thyrotoxicosis occurs in upto 23% of patients 
receiving amiodarone. 
LITHIUM 
In patients with pre existing thyroid autoimmunity lithium may increase 
serum thyroid antibody concentrations and lead to subclinical or overt 
hypothyroidism. The prevalence ranges from 10-33%. 
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RADIATION THYROIDITIS 
It is caused either during treatment with radio active iodine for 
hyperthyroidism or while receiving external beam radiation it is for certain 
cancers. It is therapy more frequently, manifests as hypothyroidism and 
occasionally thyrotoxicosis. Diagnosis is made by altered thyroid function 
Levothyroxine sodium is given as treatment. 
POST-PARTUM THYROIDITIS 
These disorders are similar and follow the same general clinical course of 
thyrotoxicosis to owed by hypothyroidism. The only real difference between 
them is that post-partum thyroiditis occurs after the delivery of a baby while 
painless thyroiditis occurs in men and in women not related to a pregnancy Not 
all patients demonstrate evidence of going through both phases; approximately 
1/3 of patients will manifest both phases: while 1/3 of patients will have only a 
thyrotoxic or hypothyroid phase. The thyrotoxic phase lasts for 1-3 months and 
is: associated with symptoms including anxiety, insomnia, palpitations (fast 
heart rate) fatigue, weight loss, and irritability The hypothyroid phase typically 
occurs 1-3 months after the thyrotoxic phase and nay last up to 9-12 months. 
Typical symptoms include fatigue, weight gain, constipation, dry skin, 
depression and poor exercise tolerance. Must patients (~80%) will have return 
of their thyroid function to normal within 12-18 months of the onset of 
symptoms. 
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PRESENTATION OF THE ANALYTICAL STUDY 
Table 1 
Incidence of type of thyroiditis in goitrous patients 
Types Incidence  
Hashimoto’s thyroiditis  24 
Dequerain thyroiditis  1 
Subacute lymphocytic  1 
 
24
1 1
Hashimoto’s thyroiditis Dequevain thyroiditis 
Subacute lympholytic 
 
This analysis shows that most common type of thyroiditis is 
hashimotos thyroiditis.  
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Table 2 
Sex distribution 
Sex No. of patients  
Female  25 
Male 1 
Total  26 
 
 Female 10 male ratio was observed as 25 :1  
25
1
Female 
Male
 
Graph showing sex distribution sex distribution of thyroiditis  
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Table 3 
Age distribution 
Age (in yrs) Female  Male  
< 20 1  
20-29 4  
30-39 16  
40-49 4 1 
> 50 1  
 
 The age of patient average from 18-55yr this analysis shows that 
leak incidence of thyroiditis is 30-40 years.  
1
4
16
4
11
0
2
4
6
8
10
12
14
16
18
<20 20-29 30-39 40-49 >50
Age in years
Female 
Male 
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Table 4 
Mode of presentation 
Symptoms  No. of patients  
Swelling 
26 
Compressive symptom  
4 
Pain  
2 
Change in voice  
- 
Toxic 
- 
 
The analysis shows that all 26 patient percent with history of 
swelling in front of neck.  2 patients with history of pain associated with 
swelling.  
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Table 5 
Clinical presentation 
Clinical presentation   No. of patients  
MNG 
20 
Diffuse enlargement  
4 
Solitary nodule  
2 
 
Out of 26 cases, 20 cases presented with MNG 4 cases as diffuse 
enlargement, 2 cases presented as solitary nodule.  
Graph showing clinical presentation 
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Table 6 
Hormonic status 
Thyroid status  No. of patients  Percentage  
Hypothyroid  
9 34.6 
Euthyroid  
16 61.5 
Hyperthyroid  
1 3.8 
 
 Out of 26 cases. 16 cases had erythroid, 9 cases are hypothroid a 1 
case had hyperthyroid.  
Graph shows thyroid hormonal status 
9
16
1
Hypothyroid
Erthyroid
Hyperthyroid
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Table 7 
FNAC status at presentation 
FNAC No. of patients  
Benign follicular cells  
4 
Hashimoto’s thyroditis  
20 
Haemorrhagic smear  
2 
 
 Out of 26 patient, 20 patients of cytopathologial diagnosis of thyroidits as 
hashimoto’s thyroiditis.  
 
Table 8 
Antimicrosomal Antibodies 
  In this study a positive antimicrosomal antibodies was positive for 
only 20 patients.  
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Table 9 
ESR status 
 No. of patients  Percentage  
Raised  
14 53.8 
Normal  
12 46 
Total  
26 100 
 
ESR was found to be elevated in about 53.8% of the cases.  
 
Table 10 
Postoperative diagnosis 
 
 No. of patients  
Preop diagnosis 
22 
Post op diagnosis  
4 
 
 Out of 26 cases, three cases FNAC found as colloid goitre, for 
subtotal thyroidectomy done and histopathology report was hashimotos 
thyroidits another one case was operated for swelling which did not 
reduce in size. 22 cases are treated medically.  
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DISCUSSION 
 
  During the study period from 2007-2009 out of 236 goitrous 
patients, 26 patient were diagnosed as thyroidits. Hashimoto’s thyroiditis 
is the most common type of thyroiditis. 
 
Out of 26 patients 24 patients was diagnosed as Hashimotos. One 
patient was diagnosed as dequervain thyroiditis and one cases was  
diagnosed as lymphocytic thyroditis.  
 Female preponderance is a well established feature of thyroid, our 
study have female preponderance, male to female ratio being 1:25. 
 In our study age incidence range from 18-55 yrs. The highest 
incidence being in 30-39 yrs.  
 All patients presented with a history of swelling in front of neck 
two patients were presented with dysphagia, another two patients were 
presented with pain over the thyroid region.  
 In our study, 20 cases are presented as multinodular swelling,              
11 patients were presented with diffuse enlargement and 2 cases were 
presented as solitary nodular swelling. 
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 In our study 16 patients are presented as euthyroid, 9 patients were 
hypothyroid and one patient with hyperthyroid. Out of 26 cases, 20 cases 
were diagnosed by FNAC as Hashimoto’s Thyrodiits and two patients as 
haemorrhagic smear.  
 In our study about 20 of the cases had thyroid autoantibiodies 
positive and ESR positivity about 53.8%. 
 The patients were followed up regularly at interval of 3 months 
about for 2 years, at every visit pulse, weight, circumference of neck were 
recorded. 
 All hypothyroid and euthyroid patient were put on ELTROXIN 
replacement (dose- 100µg) after treatment all patients were found to 
clinically euythroid after 3 months.  
 All patients with diffuse goitre and solitary nodule put on throxine 
showed a decrease in size of gland that was appreciated by measuring the 
girth of neck. 
 Four patients underwent surgery, of these three were colloid goitre 
and under went subtotal thyroidectomy, later diagnosed as hashimoto’s 
thyroidits by post operative histopathology. Surgery done for one patient 
for compressive symptoms.  
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CONCLUSION 
 
- Hashimoto’s thyroiditis is a most common type of thyroidits in 
goitrous patient.  
- Female are more prone to develop  
- Maximum incidence age group of about 30 to 40 years. 
- Thyroiditis has a varied presentation as diffuse goitre, multinodular 
goitre or a Solitary nodular goitre. 
- Thyroiditis could present as in hypothyroid, euthyroid and 
hyperthyroid state.  
- Diagnosis of thyroiditis could be done by FNAC, Antibody titre, 
ESR, histopathology report.  
- Treatment is primarily medical with thyroxine replacement and 
surgery is required with patient having pain, difficulty in 
swallowing and not regressing with eltroxin.   
 
 
 
 
Characteristics  Hashimotos  Painless postpartum  Subacute  Suppurative  Riedel’s  
Age at onset (yrs) All ages  Childbearing age  20-60 Children 20-40 30-60 
Sex ration (F:M) 8-9:1 - 5:1 1:1 3-4:1 
Cause  Auto immune  Auto immune  Unknown  Infectious  Unknown  
Pathological 
findings  
Lymphocytic 
infiltration, 
germinal centers 
Thyrotoxicosis, 
hypothyroid or both  
Thyrotoxicosis, 
hypothyroid  
Or both  
Usually 
euthyroidism  
Usually 
euthyroidism 
TPO High titer  High titer Low titer  Absent  Usually  
 
 
 
 
 
 
 
 
 
 
 TYPE 
 
CAUSE 
 
CLINICAL FEATURES 
DIAGNOSIS   
(Not All Tests May Be 
Needed) 
DURATION AND 
RESOLUTION 
 
Hashimoto’s 
thyroidits 
Anti-thyroid 
antibodies, 
autoimmune disease 
Hypothyroidism, rare cases of 
transient tinyrotoxicosis 
Thyroid function tests, 
thyroid, anti body test 
Hypothyroidism is 
usually permanent 
 
Subacute 
thyroditis 
(de 
Quervain’s 
thyroiditis) 
Possible viral cause Painful thyroid, thyrotoxicosis 
followed by hypothyroidism 
Thyroid function tests, 
sedimentation rate, radio 
active iodine uptake 
Resolves to normal 
thyroid function within 
12-18 months, 5% 
possibility of permanent 
hypothyroidism. 
Silent 
thyroiditis, 
[Painless 
thyroditis] 
Anti thyroid 
antibodies, 
autoimmune disease 
Thyrotoxicosis followed by 
hypothyroidism 
Thyroid function tests, 
thyroid antibody tests, 
radio active iodine uptake
Resolves to normal 
thyroid function within 
12-18 months, 20% 
possibility of permanent 
hypothyroidism. 
Post partum 
thyroiditis 
Anti thyroid 
antibodies, 
autoimmune disease 
Thyrotoxicosis followed by 
hypothyroidism 
Thyroid function tests, 
thyroid antibody tests, 
radio active iodine 
Resolves to normal 
thyroid function within 
12-18 months, 20% 
uptake(contra indicated if 
the women is breast – 
feeding) 
possibility of permanent 
hypothyroidism. 
Drug induced Drug include 
amiodarone, lithium, 
interferons, 
cytokines 
Either thyrotoxicosis or 
hypothyroidism 
Thyroid function tests, 
thyroide antibody tests 
Often continues as long 
as the drug is taken 
Radiation 
induced 
Follows treatment 
with radioactive 
iodine for 
hyperthyroidism or 
external beam 
radiation therapy for 
certain cancers. 
 
Occasionally thyrotoxicosis, 
more frequently 
hypothyroidism 
Thyroid function tests Thyrotoxicosis is 
transient, 
hypothyroidism is 
usually permanent 
Acute 
thyroiditis, 
suppurative 
thyroiditis 
Bacteria mainly but 
any infectious 
organism 
Occasionally painful thyroid, 
generalized illness, occasional 
mild hypothyroidism 
Thyroid function tests, 
radioactive iodine uptake, 
fine needle aspiration, 
biopsy 
Resolves after treatment 
of infectious cause, may 
cause severe illness 
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A CASE OF HASHIMOTO’S THYRIDITIS   
POST OPERATIVE PICTURE 
PROFORMA 
Name   :       Age:   Sex: 
l.P.No. : 
Address : 
 
History 
Chief Complaints  : 
Significant History  : 
Compressive Symptoms : 
 
Examination 
General Examination : 
Vital Signs  : 
Signs of hyper/ 
Hypothyroidism  : 
Examination of the Neck : 
Thyroid size  : 
Tenderness  : 
Consistency  : 
Nodularity  : 
Regional Nodes : 
Other significant findings : 
Other systemic examination : 
CVS     : 
RS     : 
Abdomen    : 
CNS     : 
Clinical Diagnosis   : 
Investigations 
1) Thyroid function tests  : 
T4    : 
T3    : 
TSH    : 
2) Anti- microsomal antibodies : 
3) USG    : 
4) FNAC    : 
5) ESR    : 
 
Diagnosis 
Operative Procedure (if done) : 
Postoperative complications (if any)  : 
HPE report of Thyroidectomy 
Specimen    : 
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HISTOPATHOLOGY OF HASHIMOTO’S 
THYROIDITIS 
  
HISTOPATHOLOGY OF DEQUERVAIN’S 
THYROIDITIS 
 
HISTOPATHOLOGY OF LYMPHOCYTIC 
THYROIDITIS 
 
  
GROSS APPEARANCE OF REIDEL’S 
THYROIDITIS 
 
HISTOPATHOLOGY OF REIDEL’S THYROIDITIS 
 
 
  
A CASE OF DIFFUSE GOITRE 
 
 
A CASE MULTI NODULAR GOITRE 
 
 A CASE OF HASHIMOTO’S THYRIDITIS   
PRE  OPERATIVE PICTURE 
 
 
A CASE OF HASHIMOTO’S THYRIDITIS   
POST OPERATIVE PICTURE 
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152 SELVI  328/09 57 F M S CO EU NTT
153 MUTHUTHURAI 235/02 43 M D S CO EU NTT
154 CHITRA 40/08 28 F M S CA EU NTT
155 DILSITH 490/07 40 F M S CO EU NTT
156 PALANIAMMAL 70/09 23 F M S CO EU NTT
157 VISALATCHI 405/07 28 F M S CO EU NTT
158 KAVERI 557/05 39 F M S CO EU NTT
159 RAMALAKSHMI 8/05 36 F M S CO EU NTT
160 ANITHA 143/09 40 F M S CO EU NTT
161 MUTHU 126/07 43 F M S CO EU NTT
162 EASWARI 527/07 30 F S S CO EU NTT
163 USHA 187/03 60 F M S CA EU NTT
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164 PARVEEN 62/07 68 F M S CO EU NTT
165 VEERAMMAL 108/07 35 F M S CO EU NTT
166 PANDESSWARI 132/08 42 F M C CO EU NTT
167 SIVARANJANI 328/09 50 F M S CO EU NTT
168 RAJAMANI 156/07 26 F M S CO HE NTT
169 SAVITHIRI 235/07 36 F M S CO EU NTT
170 MADAVI 260/08 40 F M S CO EU NTT
171 VALLI 367/09 46 F M S CO EU NTT
172 RATHINAM 132/07 37 F M S CO EU NTT
173 NAGAMMAL 127/09 40 F S S CO EU NTT
174 KANIKA 148/07 32 F M S CO EU NTT
175 KAMALAM 101/07 39 F M C CO EU NTT
176 MARIMUTHU 9/07 27 F M S CO EU NTT
177 PAVOON 349/05 45 F M S CO EU NTT
178 MOOKAYEE 128/07 50 F M S CO EU NTT
179 GAYATHIRI 517/05 37 F M S H HO Med
180 VASANTHI 151/05 39 F M D C EU NTT
181 REEKA 131/09 28 F S S H HO Med
182 KARTHIKA 43/09 31 F M S H EU Med
183 MUTHULAKSHMI 520/08 56 F D S C HO NTT
184 MARIAMMAL 7/07 33 F M S H EU Med
185 LATHA 28/07 49 F M S H EU Med
186 NAGAVALLI 285/05 34 F M S H HO Med
187 CHANDRA 111/08 43 F M S CO EU NTT
188 SUDHA 62/08 27 F S S CA EU NTT
189 VELMANI 30/07 30 F S S CO EU NTT
190 PALANIAMMAL 22/08 35 F S S CO EU NTT
191 RUKKUMANI 40/08 36 F M S CO EU NTT
192 SELUBUMSELVI 80/06 35 F M S CO EU NTT
193 KAMATCHI 527/08 60 F M S CO EU NTT
194 NAGAMMAL 560/07 27 F M S CO EU NTT
195 PRIYA 9/06 47 F M S CO EU NTT
196 PALAMAL 145/08 35 F M S CA EU NTT
197 MUTHULAXMI 148/08 30 F D D CO EU NTT
198 USHA 62/07 69 F M S CO EU NTT
199 SHANTHI 102/07 40 F M S CO EU NTT
200 JEEVA 28/07 20 F M S CO EU NTT
201 SALIMA 459/08 40 F S S CO EU NTT
202 KAMALAM 347/07 37 F S S CO EU NTT
203 SELVI 40/08 50 F M S CO EU NTT
204 CHITRA 73/05 23 F M S CO EU NTT
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205 VASANTHI 40/07 32 F M S CO EU NTT
206 CHELLAMA 6/08 29 F M S CO EU NTT
207 VIMALA 33/05 55 F S S CO EU HT
208 MOHAN 37/07 45 F M S CO EU NTT
209 SUTHIRADEVI 68022 34 F M S CO EU NTT
210 JEYACHITRA 46322 32 F M S CO EU NTT
211 MARIYA 101913 37 F M S CO EU NTT
212 SUBBULAKSHMI 13225 24 F D S CO HO Med
213 SANTRA 72310 32 F M C CO EU NTT
214 SULTA 150/01 40 F M S CO EU NTT
215 DURGA 26686 32 F M S CA EU NTT
216 PADMA 43592 67 F M S CO EU NTT
217 PREETHI 13592 46 F M S CO EU NTT
218 SANTHI 268948 43 F M S CO EU NTT
219 MEENATCHI 89/98 40 F S S CO EU NTT
220 LAKSHMI 4756 24 F M S CO EU Med
221 PREMA 18032 35 F M S CO EU NTT
222 MUNEESWARI 1349 60 F M S CO HO NTT
223 KALEESWARI 2109 44 F M S CO EU NTT
224 JEYALAKSHMI 3707 49 F M S CA EU NTT
225 ROHINI 75451 34 F S S CO EU NTT
226 SHANTHI 14223 39 F M S CO EU NTT
227 PETCHIAMMAL 182/09 32 F M M CO EU NTT
228 MUNIYASAMY 183/09 44 M M S CO EU NTT
229 VANESWARI 41929 63 F M S CA EU NTT
230 HASEENA 367/07 51 F M S CO EU NTT
231 MUTHURANI 128/07 34 F M S CO EU NTT
232 SAKUNTHALA 421/08 36 F M S CO EU NTT
233 VIJAYA 311/08 35 F M S CO EU NTT
234 VELAMMAL 70/07 47 F M S CO EU NTT
ABBREVIATIONS
PRESENTATION :  M - Multi nodular goitre ; D - Diffuse goitre ; S - Solitary Nodular goitre
CLINICAL FEATURES : S - Swelling ;  P - Pain ; D - Dysphagia
THYROID STATUS : EU - Euthyroid ; HO - Hypothyroid ; HE - Hyperthyroid
Rx  : - NTT - Near Total Thyroidectomy ; HT - Hemi thyroidectomy
CYTOLOGICAL DIAGNOSIS : H - Hashimoto's ; L - Lymphocytic ; D - Dequervain ;               
CO - Colloid ; CA - Carcinoma
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